Tumor Cell Or Cancer Cell Patents (Class 435/7.23)
-
Publication number: 20140220598Abstract: The present invention provides a biological substance detection method for specifically detecting a biological substance from a pathological specimen, by which method, when immunostaining using a fluorescent label and staining for morphological observation using a staining agent for morphological observation are simultaneously performed, the results of fluorescence observation and immunostaining can be assessed properly even if the fluorescent label and/or the staining agent is/are deteriorated by irradiation with an excitation light. The biological substance detection method according to the present invention is characterized in that the brightness retention rate of an immunostained part is in a range of 80% to 120% in relation to the brightness retention rate of apart stained for morphological observation when the fluorescent label used for the immunostaining is observed.Type: ApplicationFiled: September 4, 2012Publication date: August 7, 2014Applicants: Tohoku University, Konica Minolta, Inc.Inventors: Kensaku Takanashi, Hisatake Okada, Yasushi Nakano, Kohsuke Gonda, Noriaki Ohuchi, Mika Watanabe
-
Patent number: 8795976Abstract: The present application provides novel human gene B7330N whose expression is markedly elevated in breast cancers. The gene and polypeptide encoded by the gene can be used, for example, in the diagnosis of breast cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of breast cancer.Type: GrantFiled: July 26, 2006Date of Patent: August 5, 2014Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
-
Publication number: 20140213472Abstract: A method for predicting the response to treatment in a patient suffering from a head or neck cancer including: obtaining a biological sample for the patient; measuring the expression level of several gene and using the measurement to predict a patient's response to treatment. The methods may include predicting the treatment response in a patient having virally-induced head or neck cancer; and/or using the prediction to treat the patient.Type: ApplicationFiled: January 28, 2014Publication date: July 31, 2014Applicant: William Beaumont HospitalInventors: JAN A. AKERVALL, Bryan J. Thibodeau, George D. Wilson
-
Publication number: 20140212896Abstract: All neoplastic cells express one or more members of a unique family of cell surface ubiquinone (NADH) oxidase proteins with protein disulfide-thiol interchange activity (ECTO-NOX proteins) that are characteristically inhibited by quinone site inhibitors with anti-cancer activity and a common amino acid sequence disclosed herein that allows for cancer-specific antibody recognition as well as for detection of certain critical reference proteins that provide loading controls. Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: Mor-NuTech, Inc.Inventors: D. James Morrè, Brandon Eugene Hostetler, James Jinpal Kim
-
Publication number: 20140212881Abstract: A system and method for capturing and analyzing a set of cells, comprising: an array including a set of parallel pores, each pore including a chamber including a chamber inlet and a chamber outlet, and configured to hold a single cell, and a pore channel fluidly connected to the chamber outlet; an inlet channel fluidly connected to each chamber inlet of the set of parallel pores; an outlet channel fluidly connected to each pore channel of the set of parallel pores; a set of electrophoresis channels fluidly coupled to the outlet channel, configured to receive a sieving matrix for electrophoretic separation; and a set of electrodes including a first electrode and a second electrode, wherein the set of electrodes is configured to provide an electric field that facilitates electrophoretic analysis of the set of cells.Type: ApplicationFiled: January 24, 2014Publication date: July 31, 2014Applicant: DeNovo Sciences, Inc.Inventors: Kalyan Handique, Priyadarshini Gogoi, Saedeh Sepehri Javdani, Yi Zhou
-
Publication number: 20140212895Abstract: The invention provides for detecting target subpopulations of cells that have high proliferative and renewal properties in animals, including circulating tumor cells, cancer stem cells, hematopoietic stem cells and endothelial progenitor cells. The invention utilizes a defined substrate and media of known property to enrich target cell subpopulations which can be used for future genetic, proteomic and morphological analyses. The method can use image-capture and analysis software to characterize cells based on physical properties, such as size, morphology and kinetic properties.Type: ApplicationFiled: January 24, 2014Publication date: July 31, 2014Applicant: Xcell Biosciences, Inc.Inventor: James Lim
-
Patent number: 8791285Abstract: An activatable nanoprobe is provided having a core component and an active agent associated with the core component via a bond configured to be cleaved upon exposure to an endogenous compound.Type: GrantFiled: June 11, 2012Date of Patent: July 29, 2014Assignee: University of Central Florida Research Foundation, Inc.Inventors: Swadeshmukul Santra, James Turkson
-
Publication number: 20140206574Abstract: The invention relates to methods of detecting cancer in a sample obtained from a subject. The invention also provides kits and reagents for detecting cancer as well as therapeutics and methods of treating cancer.Type: ApplicationFiled: August 31, 2012Publication date: July 24, 2014Inventors: Karen Chapman, Joseph Wagner, Michael West, Markus Daniel Lacher, Jennifer Lorie Kidd, Maria J. Prendes
-
Publication number: 20140206620Abstract: The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.Type: ApplicationFiled: March 21, 2014Publication date: July 24, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Steven A. Rosenberg, Richard A. Morgan, Timothy L. Frankel
-
TREATMENT OF PROSTATE CANCER AND A METHOD FOR DETERMINING THE PROGNOSIS FOR PROSTATE CANCER PATIENTS
Publication number: 20140206623Abstract: The present invention relates to a Wnt5a protein or peptide thereof possessing Wnt5a signaling properties, such as Foxy5, for use in the treatment of prostate cancer, in particular in patients that have undergone or will undergo radical prosteatectomy. The invention also relates to a method for determining a prognosis for a patient having prostate cancer and a kit for performing said method. The method for determining a prognosis for a patient comprises the steps of: evaluating an amount of Wnt5a protein present in at least part of a sample earlier obtained from the patient and determining a sample value corresponding to the evaluated amount; comparing the sample value obtained in step a) with a reference value associated with a reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said patient is better than said reference prognosis.Type: ApplicationFiled: June 28, 2012Publication date: July 24, 2014Applicant: WNTRESEARCH ABInventors: Tommy Andersson, Anders Bjartell -
Publication number: 20140205592Abstract: The present invention relates to a method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. Said detection of the expression of the E-cadherin protein in a cancer sample of a cancer patient is preferably conducted by way of an immunohistochemistry (IHC) method. Said IHC method preferably employs a primary antibody which is specific for E-cadherin and a secondary antibody which specifically reacts with the primary antibody. The present invention also relates to a method of treating a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2, comprising administering to the patient a therapeutically effective amount of a PTK2 inhibitor.Type: ApplicationFiled: March 21, 2014Publication date: July 24, 2014Applicant: Boehringer Ingelheim International GmbHInventors: Guenther ADOLF, Pilar GARIN-CHESA, Ulrich HIRT
-
Publication number: 20140206008Abstract: The present invention relates to the identification of novel oral cancer and periodontal disease biomarkers. Further, the present invention provides novel methods of diagnosing and for providing a prognosis for oral cancer and periodontal disease. The present invention additionally provides novel methods of distinguishing between oral cancer and periodontal disease. Finally, kits are provided that find use in the practice of the methods of the invention.Type: ApplicationFiled: January 31, 2014Publication date: July 24, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Shen Hu, David T.W. Wong
-
Publication number: 20140206545Abstract: The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.Type: ApplicationFiled: December 18, 2013Publication date: July 24, 2014Applicants: NSABP FOUNDATION, INC., GENOMIC HEALTH, INC.Inventors: Joffre B. BAKER, Wayne COWENS, Kim M. CLARK-LANGONE, James HACKETT, Drew WATSON, Soonmyung PAIK
-
Publication number: 20140199310Abstract: We disclose agents that inhibit the expression of NETO-2 which has elevated expression in cancer stem cells; the use of NETO-2 as a diagnostic or prognostic marker of tumour initiation; the use NETO-2 polypeptides in the identification of agents that inhibit activity; and including antibodies that bind NETO-2 and vaccines comprising NETO-2 polypeptides.Type: ApplicationFiled: March 27, 2014Publication date: July 17, 2014Applicant: University of YorkInventors: Richard Birnie, Norman Maitland
-
Publication number: 20140199330Abstract: Using phosphoproteomics, we profiled the phosphorylation levels of hundreds of proteins concurrently across an isogenic model of breast cancer metastasis. Among them is TRPV4, a calcium channel that we found to be overexpressed in invasive breast tumors compared to ductal carcinoma in situ, a pre-neoplastic lesion and normal tissues. TRPV4 was also found to be elevated mostly in invasive breast cancer cell lines and less so in non-invasive breast cancer cell lines. These data led us to hypothesize that TRPV4 confer early traits of metastatic cancer cells. Functional studies revealed that silencing of TRPV4 expression diminished breast cancer cell migration and invasion significantly but not proliferation. Silencing expression of TRPV4 in metastatic breast cancer cells also reduced the number and size of metastatic colonies in mice. This supports the notion that TRPV4 is an attractive drug target to curb metastasis.Type: ApplicationFiled: August 24, 2012Publication date: July 17, 2014Applicant: National University of SingaporeInventor: Yoon Pin Lim
-
Publication number: 20140199714Abstract: A method for detecting a sentinel lymph node generating a microenvironment suitable for micrometastasis within the sentinel lymph node of carcinoma cells from a primary tumor or for detecting micrometastasis within the sentinel lymph node. A detecting agent is injected into the primary tumor, or tissue or a lymph node nearby the tumor, which allows the detecting agent to reach the sentinel lymph node by lymphatic circulation. The detecting agent includes colloid particles, an anti-ICAM-1 antibody or an ICAM-1 ligand exposed on an outer surface of the colloid particles, and a detectable label. Positive detection of the detectable label within the lymph vessel or the sentinel lymph node indicates that ICAM-1 is present, and the presence of ICAM-1 indicates that the sentinel lymph node is generating a microenvironment suitable for micrometastasis within the sentinel lymph node of carcinoma cells from the primary tumor or that micrometastasis is occurring within the lymph node.Type: ApplicationFiled: February 18, 2014Publication date: July 17, 2014Applicant: SHINSHU UNIVERSITYInventors: Toshio OHHASHI, Yoshiko KAWAI
-
Publication number: 20140199242Abstract: Novel antibodies for the detection and/or treatment of a cancer (e.g., a pancreatic cancer or an ovarian cancer) are provided. In certain embodiments the antibodies bind a region of the MUC4 protein that does not comprise the central tandem repeat (TR) domain of MUC4. Certain antibodies bind to the MUC4 peptide fragment MUC4-?-N-Ter and/or to the MUC4 peptide fragment MUC4-?-C-Ter. Chimeric constructs comprising such antibodies are also provided.Type: ApplicationFiled: June 6, 2012Publication date: July 17, 2014Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Surinder K. Batra, Maneesh Jain, Moorthy P. Ponnusamy
-
Publication number: 20140199238Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).Type: ApplicationFiled: March 19, 2014Publication date: July 17, 2014Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
-
Patent number: 8778620Abstract: The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.Type: GrantFiled: May 17, 2012Date of Patent: July 15, 2014Assignee: Nodality, Inc.Inventors: Wendy J. Fantl, David B. Rosen, Alessandra Cesano, Santosh K. Putta, Garry Nolan, Aileen Cohen, Erik Evensen
-
Patent number: 8778606Abstract: The at home cancer test permits a layperson to qualitatively test for the presence of carcinoma in the privacy of their home. The test includes a test strip coated or impregnated with at least one monoclonal antibody that binds to ?-hCG/CGH found in the patient's urine, together with a chromophore that provides a color indicator when such binding takes place. The at-home cancer test may comprise a kit containing one or more of the following: a test strip with a tab that can be gripped by the user while the strip is placed in a stream of urine; a cup for collecting urine and a test strip that may be partially immersed in the cup; and a cup for collecting urine, a test strip, and a medicine dropper or pipette for transferring the urine to the test strip.Type: GrantFiled: July 27, 2006Date of Patent: July 15, 2014Inventor: John A. Swetledge
-
Patent number: 8778621Abstract: The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone-sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone-sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone-sensitive prostate cancer as well as an immunoassay for stratifying an individual with such prostate cancer.Type: GrantFiled: May 11, 2010Date of Patent: July 15, 2014Assignee: Koninklijke Philips N.V.Inventors: Ralf Hoffmann, Miles Douglas Houslay, David James Peter Henderson
-
Publication number: 20140193837Abstract: A composition is disclosed which is capable of being used for detection, comprising a noble metal nanoparticle. The inventive compositions exhibit little interaction with serum proteins while exhibiting pH-dependent adsorption onto live cell membranes. The nanoparticles of the claimed invention are capable of interacting with cell membranes, which in turn permits the advantages of nanoparticle bio-imaging to be extended to many pH dependent biological processes such as targeting acidic tumor microenvironment.Type: ApplicationFiled: June 14, 2012Publication date: July 10, 2014Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventor: Jie Zheng
-
Publication number: 20140194317Abstract: A method of detecting the presence of specific human papilloma virus and host cell biomarkers associated with head and neck tumors in biological samples, like saliva, blood or biopsy tissue, obtained from a subject.Type: ApplicationFiled: January 23, 2014Publication date: July 10, 2014Applicant: LOMA LINDA UNIVERSITYInventors: Penelope J. Duerksen-Hughes, Maria Filippova, Valeri Filippov
-
Publication number: 20140193432Abstract: The present invention provides: antibodies specifically reacting against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies, and in particular, humanized anti-hDlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent, a tumor diagnostic agent and an agent for inducing apoptosis in tumor cells, each of which comprises the aforementioned antibody or the like; a method for treating tumor, a method for detecting tumor, a method for inducing apoptosis in tumor cells, a kit for detecting and/or diagnosing tumor and a kit for inducing apoptosis in tumor cells, each of which comprises the use of the aforementioned antibody or the like; etc.Type: ApplicationFiled: October 3, 2013Publication date: July 10, 2014Applicant: LIVTECH, INC.Inventors: Koji NAKAMURA, Hiroyuki YANAI, Toru KANKE, Naoya TSURUSHITA, Shankar KUMAR
-
Publication number: 20140193425Abstract: Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (ALK1) antagonist are provided. Methods for selecting a subject for treatment with an ALK1 antagonist based on the subject being identified as responsive to such treatment are also provided. Some of the diagnostic methods provided herein are based on detecting an ALK1 agonist, e.g., an ALK1 ligand such as BMP9 or BMP10, in a sample obtained from the subject. Diagnostic reagents and kits for determining whether a subject is responsive to treatment with an ALK1 antagonist are also provided.Type: ApplicationFiled: October 4, 2013Publication date: July 10, 2014Applicant: Acceleron Pharma, Inc.Inventors: John Knopf, Ravindra Kumar, Robert S. Pearsall, Matthew L. Sherman
-
Publication number: 20140194366Abstract: The present invention generally relates to methods, assays, compositions and kits related to a subpopulation of ovarian cancer stem cells which are selected or enriched by chemotherapeutic agents and inhibited by MIS (Mullerian Inhibiting Substance) and MIS mimetics. In particular, the present invention relates to a population of CD44+/CD24+/EpCam+/ECad? subpopulation of ovarian cancer stem cells. The present invention also provides methods to screen a subject with ovarian cancer to identify if they have an ovarian cancer comprising CD44+/CD24+/EpCam+/ECad? ovarian cancer stem cells, and methods to identify and enrich or isolate for such ovarian cancer cell populations.Type: ApplicationFiled: June 1, 2012Publication date: July 10, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Patricia K. Donahoe, David T. MacLaughlin, Jose Teixeira
-
Publication number: 20140193433Abstract: The present invention relates to methods for the stratification of a multiple myeloma (MM) patient comprising determining whether or not B-cells, preferably malignant B-cells of said patient express BCMA protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (MM) therapy is based on whether or not BCMA is expressed on the cell surface of B-cells, preferably malignant B-cells of a patient. Furthermore, antibody-based therapies for patients who have BCMA positive malignant B-cells are provided.Type: ApplicationFiled: January 8, 2014Publication date: July 10, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Eric BORGES, Jasmin Barbara HEBEIS
-
Patent number: 8772455Abstract: The present disclosure relates to a combination of biological markers for identification of prognosis of cancer. The present disclosure further relates to a method of identifying the said markers, a method of predicting prognosis and a method of planning personalized treatment for cancer. The present disclosure further relates to a kit/test comprising the antibodies against/other methods of detecting said markers for the said prediction.Type: GrantFiled: March 27, 2012Date of Patent: July 8, 2014Assignee: Oncostem Diagnostics (Mauritius) Pvt. Ltd.Inventor: Manjiri Bakre
-
Patent number: 8771963Abstract: In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells.Type: GrantFiled: September 27, 2011Date of Patent: July 8, 2014Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
-
Publication number: 20140186857Abstract: The present invention provides a fluorescent label that can be used for carrying out a biological substance detection method for specifically detecting a biological substance from a pathological specimen, by which method, when immunostaining using a fluorescent label and staining for morphological observation using a staining agent for morphological observation are simultaneously performed, the results of fluorescence observation and immunostaining can be assessed properly even if the fluorescent label and/or the staining agent is/are deteriorated by irradiation with an excitation light. The fluorescent label is a fluorescent dye-containing nanoparticle in which the parent material is a cross-linked polymer and the fluorescent dye is an aromatic ring-based dye molecule. The cross-linked polymer is suitably a melamine resin or a styrene resin. The aromatic ring-based dye molecule is suitably a perylene and more suitably a perylene diimide.Type: ApplicationFiled: March 7, 2014Publication date: July 3, 2014Applicant: Konica Minolta, Inc.Inventors: Kensaku TAKANASHI, Hisatake OKADA, Yasushi NAKANO
-
Patent number: 8765389Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for said products. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors and to the coding nucleic acids for said proteins, polypeptides and peptides.Type: GrantFiled: September 10, 2004Date of Patent: July 1, 2014Assignee: Ganymed Pharmaceuticals AGInventors: Öezlem Tüereci, Ugur Sahin, Michael Koslowski
-
Patent number: 8765388Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of VHZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of VHZ in the cell.Type: GrantFiled: August 8, 2008Date of Patent: July 1, 2014Assignee: Agency for Science, Technology and Research (A*Star)Inventor: Qi Zeng
-
Patent number: 8765390Abstract: Squamous carcinoma stem cells (SCSC) are identified. The cells can be prospectively isolated or identified from primary tumor samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and to form unique histological microdomains useful in cancer diagnosis.Type: GrantFiled: December 10, 2007Date of Patent: July 1, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Laurie Ailles, Irving L. Weissman, Michael Clarke
-
Patent number: 8765391Abstract: A method and kit for assaying a cell sample for the presence of at least a threshold number of cells of a given type are disclosed. The kit includes an assay device having a sample chamber for receiving the cell sample and an elongate collection chamber containing a selected-density and/or viscosity medium and having along its length, a plurality of cell-collection regions, and particles which are capable of specific attachment to cells of the selected cell type, and which are effective, when attached to the cells, to increase the density or magnetic susceptibility of the cells. In operation, particle-bound cells and particles in the cell sample are drawn through the elongate collection chamber under the influence of a gravitational or selected centrifugal or magnetic-field force until the particle-bound cells and particles completely fill successive cell-collection regions in the collection chamber.Type: GrantFiled: August 20, 2010Date of Patent: July 1, 2014Assignee: Zyomyx, Inc.Inventors: Frank Zaugg, Renee Tobias, Silvia McManus-Munoz, Peter Kernen, Laurence Ruiz-Taylor, Peter Wagner
-
Publication number: 20140178865Abstract: A central question in cancer therapy is how individual cells within a population of tumor cells respond to drugs designed to arrest their growth. However, the absolute growth of cells, their change in physical mass, whether cancerous or physiologic, is difficult to measure directly with traditional techniques. Embodiments of the invention provide live cell interferometry (LCI) for rapid, realtime quantification of cell mass in cells exposed to a changing environment. Overall, LCI provides a conceptual advance for assessing cell populations to identify, monitor, and measure single cell responses, such as to therapeutic drugs.Type: ApplicationFiled: August 2, 2012Publication date: June 26, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jason C. Reed, Michael A. Teitell
-
Publication number: 20140178900Abstract: Provided are an analysis device and an analysis method. According to the device and the method, a giant magnetoresistance (GMR) sensor unit is formed to be the same as the size of one cancer cell or smaller and magnetic resistance according to the number of magnetic nano particles coupled with the one cancer cell by using the GMR sensor unit, thereby not only diagnosing cancer but also simply and cheaply distinguishing the type of the cancer.Type: ApplicationFiled: July 23, 2013Publication date: June 26, 2014Applicant: Electronics and Telecommunications Research InstituteInventors: Moon Youn JUNG, Seungkyoung YANG, Kibong SONG
-
Publication number: 20140178901Abstract: This invention relates to methods for diagnosing cancer, e.g., cancer of epithelial origin, by detecting the presence of tumor cells in a sample, based (at least in some embodiments) on the quantification of levels of four biomarkers, MUC1, EGFR, EpCAM, and HER2. In some embodiments, the methods are performed using diagnostic magnetic resonance (DMR), e.g., with a portable relaxometer or MR imager.Type: ApplicationFiled: March 21, 2012Publication date: June 26, 2014Applicant: The General Hospital CorporationInventors: Ralph Weissleder, Hakho Lee, Cesar Castro
-
Publication number: 20140178366Abstract: The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.Type: ApplicationFiled: December 17, 2013Publication date: June 26, 2014Applicant: SYNTA PHARMACEUTICALS CORP.Inventors: Ronald K. Blackman, Vojo Vukovic
-
Publication number: 20140178394Abstract: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.Type: ApplicationFiled: May 31, 2012Publication date: June 26, 2014Applicants: UNIVERSITE D'AIX MARSEILLE, INSERM (Insititut Nationa de la Sante et de la Rec Recherche Medicals), INSTITUT JEAN PAOLI & IRENE CALMETTESInventors: Marc Lopez, Daniel Olive
-
Patent number: 8759006Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: July 8, 2008Date of Patent: June 24, 2014Assignee: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Owen N. Witte
-
Patent number: 8759004Abstract: The present invention relates to compounds and methods for detection and treatment of carcinomas and their precursor lesions. The invention provides DNase nucleic acids and polypeptides useful for the detection and treatment of carcinomas and their precursor lesions. The invention is more specifically related to a method for detection of carcinomas and their precursor lesions comprising the detection of the level and/or the subcellular localization of one or more DNase molecules in biological samples. Furthermore the present invention provides methods for early diagnosis, prognosis and monitoring of the disease course of carcinomas and their precursor lesions as well as for the treatment of said lesions.Type: GrantFiled: October 29, 2007Date of Patent: June 24, 2014Inventor: Johannes Coy
-
Publication number: 20140170114Abstract: The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3.Type: ApplicationFiled: February 17, 2014Publication date: June 19, 2014Applicant: The Trustees of the University of PennsylvaniaInventor: David Kaplan
-
Publication number: 20140170676Abstract: The present disclosure relates, in one of its aspects, to a method for determining whether a mammalian subject having a bladder cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: a) evaluating an amount of RBM3 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the second group.Type: ApplicationFiled: May 11, 2012Publication date: June 19, 2014Applicant: Atlas Antibodies ABInventors: Jakob Eberhard, Karin Jirström
-
Publication number: 20140170677Abstract: The present invention relates to the use of a novel, isolated anti-CXCR4 antibody in the diagnosis of cancer. In particular, methods for diagnosing and/or prognosing an oncogenic disorder associated with CXCR4 expression, are disclosed.Type: ApplicationFiled: July 30, 2012Publication date: June 19, 2014Applicant: PIERRE FABRE MEDICAMENTInventors: Christine Klinguer-Hamour, Alexandra Jouhanneaud
-
Publication number: 20140170066Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.Type: ApplicationFiled: February 24, 2014Publication date: June 19, 2014Applicants: Merck & Co., Inc., Visen Medical, Inc.Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
-
Publication number: 20140170639Abstract: The invention generally relates to methods for indicating whether an assay for isolating targets is properly isolating and detecting targets. Methods of the invention involve obtaining a sample suspected of a containing target, introducing a detectable marker into the sample, conducting an assay using magnet particles to isolate the detectable marker and the target if it is present in the sample, determining the presence or absence of the target; and confirming that the assay functioned properly by determining presence or absence of the detectable marker.Type: ApplicationFiled: December 12, 2013Publication date: June 19, 2014Applicant: NANOMR, INC.Inventor: Meghan Norvell
-
Publication number: 20140170135Abstract: The subject invention provides a method for treating a patient having a tumor associated with HER2+ breast cancer comprising: measuring in a sample of the patient's tumor a level of expression of epidermal growth factor receptor protein by using an antibody that detects the cytoplasmic domain of epidermal growth factor receptor; and comparing the level of expression of epidermal growth factor receptor protein in the patient's tumor so measured with a reference value; wherein if the level of expression of epidermal growth factor receptor measured is higher than the reference value, treating the patient with a therapy other than trastuzumab.Type: ApplicationFiled: December 5, 2013Publication date: June 19, 2014Applicant: YALE UNIVERSITYInventors: David L. RIMM, Huan CHENG, Anastasios DIMOU, Valsamo ANAGNOSTOU
-
Patent number: 8753822Abstract: A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease selected from the list in Table 6. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays of claim 4, the software including analyzing means for analyzing the arrays.Type: GrantFiled: June 20, 2011Date of Patent: June 17, 2014Assignee: Wayne State UniversityInventors: Michael Tainsky, Sorin Draghici, Madhumita Chatterjee
-
Patent number: 8753829Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: GrantFiled: December 4, 2012Date of Patent: June 17, 2014Assignee: Alper Biotech, LLCInventor: Özge Alper
-
Patent number: 8753830Abstract: Cdc25A is herein identified as a substrate for ?-TrCP1- or ?-TrCP2-mediated ubiquitination and subsequent degradation via the ubiquitin-proteasome pathway. In particular, it has been found that interfering with ?-TrCP expression or function, or increasing ?-TrCP degradation, leads to accumulation of Cdc25A in a cell. Since degradation of Cdc25A is a key feature of the response to DNA damage, leading to a stall in the cell cycle during which the cell can repair the damage, Cdc25A accumulation can abolish this response, thereby sensitizing the cell to DNA damage. Described herein are assays for identifying ?-TrCP inhibitors, and method of using such inhibitors for modulating Cdc25A degradation, sensitization of tumor cells, and as adjuvants in cancer therapy based on DNA damaging agents.Type: GrantFiled: May 3, 2013Date of Patent: June 17, 2014Assignee: New York UniversityInventors: Michele Pagano, Luca Busino